Argenx Nears Phase III In Myasthenia Gravis

 
• By John Davis
Acetylcholine
Antibodies against acetylcholine receptors in neuromuscular junctions are a cause of myasthenia gravis • Source: Shutterstock

More from Clinical Trials

More from R&D